A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Dubernet et al.,
A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or..,
J. Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.08.001
Retrospective analysis of 36 hospitalized patients showing HCQ/AZ associated with lower ICU admission,
p=0.008. Median age 66, no mortality.
Confounding by indication, however it was patients with hypoxemic pneumonia that were treated with HCQ/AZ, patients were not treated with HCQ/AZ if they didn't need oxygen therapy.
risk of ICU admission, 87.6% lower, RR 0.12, p = 0.008, treatment 1 of 17 (5.9%), control 9 of 19 (47.4%), NNT 2.4.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Dubernet et al., 20 Aug 2020, retrospective, France, peer-reviewed, median age 66.0, 20 authors.
Abstract: Journal of Global Antimicrobial Resistance 23 (2020) 1–3
Contents lists available at ScienceDirect
Journal of Global Antimicrobial Resistance
journal homepage: www.elsevier.com/locate/jgar
Short Communication
A comprehensive strategy for the early treatment of COVID-19 with
azithromycin/hydroxychloroquine and/or corticosteroids: Results of a
retrospective observational study in the French overseas department of
Réunion Island
Arthur Duberneta , Kevin Larsena , Laurie Massea , Jérôme Allynb,c , Emilie Focha ,
Lea Bruneaud,e, Adrien Maillote, Marie Lagrange-Xelotf , Vincent Thomasg ,
Marie-Christine Jaffar-Bandjeeg , Loraine Gauzereh , Loic Raffrayh , Karine Borsui ,
Servane Dibernardoi , Stéphane Renaudj , Michel Andréa , Diane Moreaua , Julien Jabotb ,
Nathalie Coolen-Alloua , Nicolas Alloub,c,*
a
Pneumologie, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France
Réanimation polyvalente, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France
c
Département d’Informatique Clinique, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France
d
INSERM CIC 1410 Clinical and Epidemiology, University Hospital, Saint Pierre, Réunion Island, France
e
Department of Public Health and Research Support, Methodological Support and Biostatistics Unit, University Hospital, Saint Denis, Réunion Island, France
f
Service des Maladies Infectieuses, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France
g
Microbiologie, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France
h
Médecine Interne, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France
i
Médecine Polyvalente, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France
j
Gériatrie, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France
b
A R T I C L E I N F O
A B S T R A C T
Article history:
Received 11 June 2020
Received in revised form 22 July 2020
Accepted 1 August 2020
Available online 20 August 2020
Background: This study aimed to evaluate the prognosis of COVID-19 patients in Reunion Island, with a
particular focus on the management of patients with hypoxemic pneumonia.
Methods: This retrospective observational study was conducted from 11 March to 17 April 2020 at the
only hospital authorized to manage patients with COVID-19 in Reunion Island.
Results: Over the study period, 164 out of 398 patients (41.2%) infected with COVID-19 were admitted to
Félix Guyon University Hospital. Of these, 36 (22%) developed hypoxemic pneumonia. Patients with
hypoxemic pneumonia were aged 66 [56–77] years, 69% were male and 33% had hypertension. Ten
patients (27.8%) were hospitalized in intensive care unit (ICU). Hydroxychloroquine/azithromycin
treatment was associated with a lower ICU admission rate (P = 0.008). None of the 6 patients treated with
corticosteroids were hospitalized in ICU (P = 0.16). There were no deaths at follow up (minimum 80 days).
Conclusions: Despite the risk profile of COVID-19 patients with severe hypoxemic pneumonia, the
mortality rate of the disease in Reunion Island was 0%. This may be due to the care bundle used in our
hospital (early hospitalisation, treatment with..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit